Literature DB >> 20358432

Statistical characteristics of moxifloxacin-induced QTc effect.

Lihan K Yan1, Joanne Zhang, Moh Jee Ng, Qianyu Dang.   

Abstract

Moxifloxacin has been the most commonly used positive control in "thorough" QTc (TQT) studies. In a TQT study, the assay sensitivity is often considered to be established if the baseline corrected mean difference in QTc between moxifloxacin and placebo is greater than 5 ms in common practice at one or more prespecified time points and the observed moxifloxacin induced QTc effect over time follows the proper pharmacokinetics profile. To better understand the statistical characteristics of moxifloxacin-induced QTc prolongation and to provide guidance for future studies, 20 TQT studies that involved moxifloxacin have been evaluated. We study the QTc profile of the baseline adjusted mean difference in QTc between moxifloxacin and placebo over time. Zhang (2008) proposed that the moxifloxacin induced QTc effect can be evaluated between 1 and 4 h after a single dose (400 mg) administration near the time (T(max)) of peak concentration instead of all time points (typically 9-12 time points) at which QT was measured for the study drug evaluation. After evaluating 20 TQT studies, we confirm that the maximum moxifloxacin effect occurs in the time window between 1 and 4 h post dose. We also investigate the variability of the data as well as correlations between time points and between regimens. These findings and results can be used as a reference for future studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20358432     DOI: 10.1080/10543400903581945

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  25 in total

1.  Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers.

Authors:  Feng-Yan Xu; Ji-Han Huang; Ying-Chun He; Li-Yu Liang; Lu-Jin Li; Juan Yang; Fang Yin; Ling Xu; Qing-Shan Zheng; Kun Wang
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

2.  Replacing the thorough QT study: reflections of a baby in the bath water.

Authors:  Robert B Kleiman; Rashmi R Shah; Joel Morganroth
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

3.  Detection of QT prolongation using a novel electrocardiographic analysis algorithm applying intelligent automation: prospective blinded evaluation using the Cardiac Safety Research Consortium electrocardiographic database.

Authors:  Cynthia L Green; Paul Kligfield; Samuel George; Ihor Gussak; Branislav Vajdic; Philip Sager; Mitchell W Krucoff
Journal:  Am Heart J       Date:  2012-02-27       Impact factor: 4.749

Review 4.  Early QT assessment--how can our confidence in the data be improved?

Authors:  Borje Darpo; Christine Garnett
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

Review 5.  Early investigation of QTc liability: the role of multiple ascending dose (MAD) study.

Authors:  Rashmi R Shah; Joel Morganroth
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

6.  ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies.

Authors:  Rashmi R Shah; Joel Morganroth
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

Review 7.  Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 8.  Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?

Authors:  Norman Stockbridge; Joel Morganroth; Rashmi R Shah; Christine Garnett
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

9.  No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.

Authors:  Manoli Vourvahis; Rong Wang; Marie-Noella Ndongo; Melissa O'Gorman; Margaret Tawadrous
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

10.  Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects.

Authors:  Jorg Taubel; Georg Ferber; Ulrike Lorch; Velislav Batchvarov; Irina Savelieva; A John Camm
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.